Gracell Biotechnologies I... (GRCL)
NASDAQ: GRCL
· Real-Time Price · USD
10.25
0.01 (0.05%)
At close: Feb 21, 2024, 10:00 PM
Gracell Biotechnologies Income Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | 366K | 366K | 366K | 366K | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | 366K | 366K | 366K | 366K | n/a | n/a |
Operating Income | -578.83M | -626.85M | -631.52M | -624.66M | -614.91M | -576.24M | -526.11M | -463.57M | -409.47M | -326.53M | -278.61M |
Interest Income | 44.94M | 38.61M | 36.05M | 23.92M | 12.25M | 11.65M | 10.68M | 9.12M | 6.11M | 3.37M | 2.64M |
Pretax Income | -496.92M | -601.24M | -600.62M | -607.49M | -605.4M | -562.76M | -512.67M | -451.75M | -406.76M | -328.05M | -277.61M |
Net Income | -496.98M | -601.56M | -599.76M | -604.04M | -601.93M | -559.01M | -510.1M | -451.75M | -406.76M | -328.05M | -277.61M |
Selling & General & Admin | 134.32M | 139.05M | 130.47M | 139.27M | 135.09M | 141.51M | 143.17M | 137.04M | 129.83M | 95.15M | 71.7M |
Research & Development | 444.51M | 487.8M | 501.06M | 485.39M | 479.83M | 435.09M | 383.3M | 326.9M | 280.01M | 231.38M | 206.91M |
Other Expenses | 630K | 630K | 630K | 144K | 144K | 877K | 829K | 813K | 813K | 303K | 351K |
Operating Expenses | 578.83M | 626.85M | 631.52M | 624.66M | 614.91M | 576.61M | 526.47M | 463.94M | 409.84M | 326.53M | 278.61M |
Interest Expense | 6.44M | 7.01M | 6.97M | 6.74M | 6.27M | 5.5M | 5.25M | 5.06M | 4.54M | 4.11M | 3.18M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 578.83M | 626.85M | 631.52M | 624.66M | 614.91M | 576.61M | 526.47M | 463.94M | 409.84M | 326.53M | 278.61M |
Income Tax Expense | 61K | 327K | -859K | -3.44M | -3.47M | -3.75M | -2.89M | -19K | -19K | 385K | 707K |
Shares Outstanding (Basic) | 16.78M | 13.63M | 13.54M | 13.54M | 13.54M | 13.53M | 13.53M | 13.15M | 13.46M | 13.45M | 12.18M |
Shares Outstanding (Diluted) | 16.78M | 13.65M | 13.54M | 13.54M | 13.54M | 13.53M | 13.53M | 13.15M | 13.46M | 13.45M | 12.18M |
EPS (Basic) | -35.65 | -44.3 | -44.25 | -44.6 | -44.7 | -41.6 | -38.05 | -34.5 | -31.6 | -25.85 | -30.25 |
EPS (Diluted) | -35.65 | -44.3 | -44.25 | -44.6 | -44.7 | -41.6 | -38.05 | -34.5 | -31.6 | -25.85 | -30.25 |
EBITDA | -525.18M | -579.71M | -586.83M | -592.58M | -590.25M | -553.67M | -506.35M | -445.39M | -390.29M | -310.59M | -261.79M |
EBIT | -499.1M | -594.22M | -593.65M | -600.75M | -599.13M | -557.26M | -507.42M | -446.69M | -402.22M | -323.94M | -274.43M |
Depreciation & Amortization | 53.64M | 47.14M | 44.69M | 32.08M | 25.27M | 23.18M | 20.36M | 18.79M | 15.81M | 12.57M | 13.46M |